Progress has been made in HIV care. However, that doesn’t mean you don’t need a detailed plan for taking care of an ...

Opioid use disorder affects more than 2 million people in the U.S. and contributes to the public health crisis of opioid ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Health authorities in Rio de Janeiro are reviewing samples from 288 donors after discovering that two HIV-positive people ...

People with HIV can safely receive donated kidneys from deceased donors with the virus, according to a large study that comes ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

The Pakistan Stock Exchange (PSX) held a gong ceremony to celebrate the listing of BF Biosciences Limited (BFBIO). BFBIO is a ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Vocea linked the theme to the rising drug-related challenges in Serua, stressing that drug abuse has far-reaching ...